Angle Plc (AGL.L) Announced that the first phase of its ovarian cancer clinical verification study has reported positive
results. The pre-study results demonstrate that the optimisation of the sample-to-answer molecular
solution has been successful, paving the way to initiate the 200 subject ovarian cancer clinical
verification study of patients who are presenting with a pelvic mass and scheduled for surgery. This
study is expected to start in early Q3 CY19 and is projected to complete in Q1 CY20.